Drug-induced long QT syndrome: Concept and nonclinical models for predicting the onset of drug-induced torsade de pointes in patients in compliance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) E14/S7B guidance

被引：1

作者：

Sugiyama, Atsushi ^{[1
,2
]}

Goto, Ai ^{[1
]}

Izumi-Nakaseko, Hiroko ^{[1
]}

Takei, Yoshinori ^{[1
,2
]}

Takahara, Akira ^{[3
]}

Kambayashi, Ryuichi ^{[1
]}

机构：

[1] Toho Univ, Fac Med, Dept Pharmacol, 5-21-16 Omori Nishi,Ota Ku, Tokyo 1438540, Japan

[2] YOKOYAMA Kazuya Canc Res Inst, Tokyo, Japan

[3] Toho Univ, Fac Pharmaceut Sci, Dept Pharmacol & Therapeut, Chiba, Japan

来源：

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS | 2025年 / 392卷 / 02期

关键词：

CiPA; ICH E14/S7B Q&As; Proarrhythmic surrogate marker; QT interval; Torsade de pointes; CHRONIC ATRIOVENTRICULAR-BLOCK; III ANTIARRHYTHMIC-DRUG; FLUOROQUINOLONE ANTIBACTERIAL AGENTS; POTENTIAL DURATION PROLONGATION; REDUCES TRANSMURAL DISPERSION; ISOLATED RABBIT HEART; IN-VIVO ANALYSIS; VENTRICULAR REPOLARIZATION; TORSADOGENIC ACTION; D-SOTALOL;

D O I：

10.1124/jpet.124.002184

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) established S7B and E14 guidelines in 2005 to prevent drug-induced torsade de pointes (TdP), effectively preventing the development of high-risk drugs. However, those guidelines hampered the development of some potentially valuable drug candidates despite not being proven to be proarrhythmic. In response, comprehensive in vitro proarrhythmia assay and exposure-response modeling were proposed in 2013 to reinforce proarrhythmic risk assessment. In 2022, the ICH released E14/S7B questions and answers (stage 1), emphasizing a "double negative" nonclinical scenario for low-risk compounds. For "non-double negative" compounds, new questions and answers are expected to be enacted as stage 2 shortly, in which more detailed recommendations for proarrhythmia models and proarrhythmic surrogate markers will be provided. This review details the onset mechanisms of drug-induced TdP, including IKr inhibition, pharmacokinetic factors, autonomic regulation, and reduced repolarization reserve. It also explores the utility of proarrhythmic surrogate markers (J-T-peak, T-peak-T-end, and terminal repolarization period) besides QT interval. Finally, it presents various in silico, in vitro, ex vivo, and in vivo models for proarrhythmic risk prediction, such as comprehensive in vitro proarrhythmia assay in silico model, induced pluripotent stem cell-derived cardiomyocyte sheet, Langendorff-perfused heart preparation, chronic atrioventricular block animals (dogs, monkeys, pigs, and rabbits), acute atrioventricular block rabbits, methoxamine-sensitized rabbits, and genetically engineered rabbits for specific long QT syndromes. Those models along with the surrogate markers can play important roles in quantifying TdP risk of new compounds, impacting late-phase clinical design and regulatory decision-making, and preventing adverse events on postmarketing clinical use. Significance Statement: Since ICH S7B/E14 guidelines hampered the development of some potentially valuable compounds with unproven proarrhythmic risk, comprehensive in vitro proarrhythmia assay and exposure-response modeling were proposed in 2013 to reinforce proarrhythmic risk assessment of new compounds. In 2022, the ICH released questions and answers (stage 1), emphasizing a "double negative" nonclinical scenario for low-risk compounds, and new questions and answers (stage 2) for "non-double negative" compounds are expected. This review delves into proarrhythmic mechanisms with surrogate markers and explores various models for proarrhythmic risk prediction. (c) 2024 The Authors. Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).

引用

页数：19

共 128 条

[31]

Farkas A, Dempster J, Coker SJ, Importance of vagally mediated bradycardia for the induction of torsade de pointes in an in vivo model, Br J Pharmacol, 154, (2008)

[32]

Fridericia LS, The duration of systole in an electrocardiogram in normal humans and in patients with heart disease. 1920, Ann Noninvasive Electrocardiol, 8, (2003)

[33]

Goto A, Hagiwara-Nagasawa M, Chiba K, Kambayashi R, Nunoi Y, Izumi-Nakaseko H, Matsumoto A, Kanda Y, Sugiyama A, Pharmacological b-adrenoceptor blockade can augment torsadogenic action of IKr inhibitor: comparison of proarrhythmic effects of d-sotalol and dl-sotalol in the chronic atrioventricular block dogs, J Pharmacol Sci, 141, (2019)

[34]

Goto A, Hagiwara-Nagasawa M, Kambayashi R, Chiba K, Izumi-Nakaseko H, Naito AT, Kanda Y, Sugiyama A, Measurement of J-Tpeakc along with QT-interval prolongation may increase the assay sensitivity and specificity for predicting the onset of drug-induced torsade de pointes: experimental evidences based on proarrhythmia model animals, Cardiovasc Toxicol, 19, (2019)

[35]

Goto A, Izumi-Nakaseko H, Hagiwara-Nagasawa M, Chiba K, Ando K, Naito AT, Sugiyama A, Analysis of torsadogenic and pharmacokinetic profile of E-4031 in dogs bridging the gap of information between in vitro proarrhythmia assay and clinical observation in human subjects, J Pharmacol Sci, 137, (2018)

[36]

Goto A, Kambayashi R, Izumi-Nakaseko H, Shinozaki M, Takei Y, Sugiyama A, Characterization of electropharmacological profile of an anti-atrial fibrillatory drug vernakalant along with potential risk toward torsade de pointes: translational studies using isoflurane-anesthetized dogs and isolated rat aortic preparations, J Pharmacol Sci, 152, (2023)

[37]

Goto A, Nakamura Y, Lubna NJ, Chiba K, Hagiwara-Nagasawa M, Izumi-Nakaseko H, Ando K, Naito AT, Sugiyama A, Analysis of safety margin of lithium carbonate against cardiovascular adverse events assessed in the halothane-anesthetized dogs, Cardiovasc Toxicol, 18, (2018)

[38]

Goto A, Sakamoto K, Hagiwara-Nagasawa M, Kambayashi R, Chiba K, Nunoi Y, Izumi-Nakaseko H, Matsumoto A, Sugiyama A, Utilization of the chronic atrioventricular block cynomolgus monkey as an in vivo model to evaluate drug interaction-associated torsade de pointes, J Pharmacol Sci, 142, (2020)

[39]

Goto A, Sakamoto K, Hagiwara-Nagasawa M, Kambayashi R, Chiba K, Nunoi Y, Izumi-Nakaseko H, Takei Y, Matsumoto A, Sugiyama A, In vivo analysis of the effects of intravenously as well as orally administered moxifloxacin on the pharmacokinetic and electrocardiographic variables along with its torsadogenic action in the chronic atrioventricular block cynomolgus monkeys, J Pharmacol Sci, 143, (2020)

[40]

Goto A, Sakamoto K, Kambayashi R, Izumi-Nakaseko H, Kawai S, Takei Y, Matsumoto A, Kanda Y, Sugiyama A, Validation of risk-stratification method for the chronic atrioventricular block cynomolgus monkey model and its mechanistic interpretation using 6 drugs with pharmacologically distinct profile, Toxicol Sci, 190, (2022)

← 1 2 3 4 5 6 7 8 9 10 →